ITeos Therapeutics Inc (NAS:ITOS)
$ 8.34 -0.21 (-2.46%) Market Cap: 304.69 Mil Enterprise Value: -170.82 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 46/100

Iteos Therapeutics Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 02:10PM GMT
Release Date Price: $17.07 (+2.65%)
Unidentified Analyst

I'm with iTeos. Please take it away.

Michel Detheux
iTeos Therapeutics, Inc. - Co-founder, President & CEO

Okay. Thank you, Nick, and good morning, everyone. I would like to thank Cowen for the opportunity to present iTeos today. And I'm very pleased to be here. While it's a small venue then we can really enjoy interacting or interactive discussion.

I founded iTeos 10 years ago with the willingness to develop better drugs. And my mission then and now has been to build a company that would master tumor immunology to select the most relevant targets and develop differentiated drugs. And I'm very proud of what we have done over the 10 last years.

During the presentation, I will make forward-looking statements. And I would like to start this presentation with a summary of why we believe we can develop better drugs. You can see here that we have everything we need for success, a deep and growing pipeline, nearly a dozen of ongoing and planned clinical trials in major indication.

And I want to draw your attention to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot